USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
DESIGNMEDIX, INC.
Address:
2828 Corbett Ave Suite 140A
PORTLAND, OR 97201-4830
Phone:
N/A
URL:
N/A
EIN:
126277928
DUNS:
623389009
Number of Employees:
4
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $102,614.00 1
STTR Phase I $703,876.00 2
STTR Phase II $4,310,664.00 2

Award List:

Designed Antimalarial Agents Overcoming Chloroquine-Resistance

Award Year / Program / Phase:
2007 / STTR / Phase I
Award Amount:
$103,876.00
Agency:
HHS
Principal Investigator:
Research Institution:
PORTLAND STATE UNIVERSITY
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The intent of the work presented in this proposal is to counter the worldwide health problem brought on by the spread of chloroquine-resistant malaria. To address the need for an orally available and inexpensive replace ment drug, we have developed a novel class… More

Designed Antimalarial Agents Overcoming Chloroquine-Resistance

Award Year / Program / Phase:
2009 / STTR / Phase II
Award Amount:
$1,327,608.00
Agency:
HHS
Principal Investigator:
Research Institution:
PORTLAND STATE UNIVERSITY
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): DesignMedix has developed a novel class of compounds to address the pressing need for an orally available, inexpensive drug to counter the spread of chloroquine-resistant malaria. Preliminary data showed that this novel class of molecules, called reversed… More

Preclinical development of novel small molecule malaria drugs that overcome drug

Award Year / Program / Phase:
2011 / STTR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
David H. Peyton – 503-725-3875
Research Institution:
PORTLAND STATE UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. This project initiates preclinical development of one or more candidate(s) from an innovative newclass of potent antimalarials designed to… More

Optimization of a novel antimalarial drug candidate for plant-scale synthesis

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$102,614.00
Agency:
HHS
Principal Investigator:
Steven Burgess – 503-484-7026
Abstract:
DESCRIPTION (provided by applicant): There is a great need for anti-malarial drugs that are inexpensive and effective against drug-resistant strains. Malaria is one of the most important diseases worldwide, with over 225 million cases each year, and about800 thousand deaths. Most of these deaths… More

Preclinical development of novel small molecule malaria drugs that overcome drug

Award Year / Program / Phase:
2014 / STTR / Phase II
Award Amount:
$2,983,056.00
Agency:
HHS
Principal Investigator:
David H. Peyton – 503-725-3875
Research Institution:
PORTLAND STATE UNIVERSITY
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine-resistant and… More